VernerisLab

Changing the practice of medicine through innovative immunological research.

[VernerisLab @VernerisLab]

@biorxivpreprint @CrnicInstitute Pre-print release of our recent collaboration with the Espinosa Lab https://t.co/7s7Ho3saTS

[VernerisLab @VernerisLab]

@RallyFoundation stopped by the CU Anschutz campus today and we had the chance to share our ongoing research. They have been an amazing partner working with us to find cures and better treatments for childhood cancers! https://t.co/VviHNW3qDx

[VernerisLab @VernerisLab]

We are still looking for eligible canine patients for our CAR T therapies in canine osteosarcoma and glioblastoma. Spread the word! https://t.co/UgRal8xVn7

[VernerisLab @VernerisLab]

A short talk with Dr. Michael Verneris:
https://t.co/5QHNSJy27f

[VernerisLab @VernerisLab]

Excited to announce Joselyn Cruz Cruz's selection for grant funding from the Rally Foundation and Infinite Love for Kids Fighting Cancer! Part of $7 million in grants distributed this year. View 2026 grants: https://t.co/sFSUuNmLRa #RallyOn #GoldStrong #CUAnschutz #immunotherapy

[VernerisLab @VernerisLab]

Excited to welcome our two new rotation students, Austin Thekkumthala and Mark Sellin!

[VernerisLab @VernerisLab]

Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR: Molecular Therapy https://t.co/Yv11KdBd5V

[VernerisLab @VernerisLab]

Surprise Grateful Dead themed birthday celebration for Mike!

[VernerisLab @VernerisLab]

Excited to share our latest publication by Dejene Tufa: Innate Lymphoid Cells Prevent Graft vs. Host Disease Via IL-9 Driven T cell Senescence
https://t.co/PnfPGhOTyO

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Differential phagocytosis induces diverse macrophage activation states in malignant gliomas https://t.co/74jekdTLGr

[VernerisLab @VernerisLab]

Our own Dr. Elena Woods presenting her work for 10X Genomics Xenium in-situ presentation.

[University of Colorado Anschutz @CUAnschutz]

In this episode of CU Anschutz 360, Terry Fry, MD, talks about the latest advances in CAR T cell therapies and how the Gates Institute offers an incredible opportunity to help patients facing serious health issues.

[VernerisLab @VernerisLab]

Excited for the latest Gates seminar! https://t.co/sxkJiWpACU

[VernerisLab @VernerisLab]

Great article on how the Gates Institute helps accelerate CU Anschutz lab discoveries into clinical applications.
https://t.co/LgHBWNo8XL

[VernerisLab @VernerisLab]

https://t.co/E13JindO9D

[VernerisLab @VernerisLab]

https://t.co/0SfB488GiR Excited to have this great talk next week!

[Thomas Flaig @TomFlaigMD]

Congratulations to @DanPollyea from the @CUCancerCenter for receiving a Career Development Achievement Award from the @LLSusa for his work to advance groundbreaking new therapies for #leukemia
https://t.co/oTHRhvMWTa

[Nature Immunology @NatImmunol]

Sun and colleagues suggest that nucleophosmin 1 expression in ILC3s regulates IL-22 production and mitochondrial function and is required for gut homeostasis and colitis prevention. Read it here: https://t.co/6SZpKbeemj
https://t.co/Ad4xF97fm6

[VernerisLab @VernerisLab]

Congrats to Jessica Lake for her paper's acceptance into @jitcancer titled "Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma."
https://t.co/4kx11XOkfZ

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma https://t.co/HeBzcYYDCp @MVerneris